BigOmics
BigOmics Analytics is a Swiss bioinformatics company founded by Murat Akhmedov (CEO) and Ivo Kwee (CTO), headquartered in Lugano.
Profile
Provides a cloud platform for biologists to analyze and visualize complex biological datasets like gene expression and protein data.
BigOmics Analytics is a Swiss bioinformatics company founded by Murat Akhmedov (CEO) and Ivo Kwee (CTO), headquartered in Lugano. The company specializes in cloud-based omics data analysis tools, with its flagship product Omics Playground enabling researchers to visualize and interpret complex datasets in transcriptomics, proteomics, and metabolomics. In October 2025, BigOmics raised $1.6M in a funding round led by Diffusion Capital Partners and TiVentures, bringing its total known funding to at least this amount.
The platform claims over 6,000 researchers and 60+ biotech/pharma clients globally, including named accounts like Sanofi, Vertex Pharmaceuticals, and AbbVie. Recent product updates in late 2024 focused on proteomics workflows and expanded species support. The company operates a freemium model where free users can upgrade to paid plans, with marketing emails explicitly noted in its privacy policy as a revenue driver. While the platform emphasizes collaborative features for biologists and bioinformaticians, its growth depends on continued adoption in a competitive bioinformatics tools market dominated by open-source alternatives and large commercial suites.
Who buys this
- Academic research labs in genomics and proteomics
- Biotechnology companies conducting drug discovery
- Pharmaceutical firms with precision medicine programs
- Clinical research organizations handling multi-omics data
Publicly disclosed clients
- Sanofi
- Vertex Pharmaceuticals
- AbbVie
- University of Oxford
- Harvard Medical School
Strengths and what to watch
Strengths
- Freemium model lowers adoption barriers for academic users
- Named enterprise clients validate clinical-grade use cases
- Recent $1.6M funding round provides runway for product development
Watch for
- Dependence on a single product (Omics Playground) with no evident diversification
- Privacy policy discloses data collection practices that may concern regulated industries
- No disclosed revenue figures despite claimed 60+ enterprise clients
Recent moves
Key Information
- Founded
- 2018
- Headquarters
- Lugano, Switzerland
Frequently Asked Questions
What is BigOmics Analytics?
BigOmics provides a cloud platform for biologists to analyze gene expression, proteomics, and metabolomics data. Founded in Switzerland, it offers Omics Playground for visualization and interpretation, serving 6,000+ researchers with freemium access. The company raised $1.6M in 2025 and counts Sanofi and Harvard among clients.
How does Omics Playground work?
The platform enables interactive analysis of complex biological datasets through visualization tools and collaborative features. Researchers upload omics data to explore patterns, with workflows supporting transcriptomics and proteomics. Recent updates expanded species support and proteomics capabilities, targeting both academic and pharmaceutical users.
Who uses BigOmics software?
Primary users include academic labs, biotech firms, and pharmaceutical companies like Vertex and AbbVie. The freemium model attracts individual researchers, while enterprise clients adopt it for drug discovery and precision medicine programs. Over 60 biotech/pharma organizations are confirmed customers.
Is BigOmics better than open-source tools?
BigOmics offers curated workflows and enterprise support lacking in open-source alternatives, with validated use cases at named clients. However, researchers needing full customization may prefer open-source options. The platform competes on usability and cloud collaboration rather than raw computational flexibility.
What are BigOmics' limitations?
The company relies solely on Omics Playground without diversified products. Data collection practices disclosed in privacy policies may concern regulated industries. While serving notable clients, revenue figures remain undisclosed despite $1.6M funding and 60+ enterprise accounts.
What's new in BigOmics' 2024 updates?
Late 2024 enhancements focused on proteomics workflows and broader species compatibility. Version 3.5 improved visualization for metabolomics data and added collaboration features for cross-institutional teams. These updates followed the October 2025 funding round aimed at product expansion.
Sources
- bigomics.ch — Freemium model details and data collection practices
- bigomics.ch — Client logos and product positioning
- bigomics.ch — $1.6M funding round and investor details
- bigomics.ch — Product capabilities and November 2024 feature updates